Loading clinical trials...

Evaluation of On-Couch CBCT Image Quality | Clinical Trials | Clareo Health

RECRUITINGNA

Evaluation of On-Couch CBCT Image Quality

Evaluation of Image Quality From an On-Couch, Cone Beam Computed Tomography (CBCT) Radiation Treatment System for Image Guidance and Treatment Adaptation

NCT06576908•Varian, a Siemens Healthineers Company

View on ClinicalTrials.gov

Summary

This is a prospective, single-arm, single-site study designed to generate data describing the image quality and applicability/useability of a high-performance, on-couch CBCT imaging technology (HyperSight) in patients receiving radiation treatment for cancer on a C-arm linear accelerator (TrueBeam).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient age is ≥ 18 years old.
•Patient has a diagnosis of primary or metastatic cancer, including but not limited to tumors arising from or involving the head/neck, lungs, liver, pancreas, prostate, urinary bladder, rectum, cervix or uterus.
•A previous (standard-of-care) decision was made to treat the patient with radiation therapy using a Varian TrueBeam treatment system.
•A previous (standard-of-care) decision was made to treat the patient with a radiation dose of at least 20 Gy in at least 5 fractions, one fraction per day on consecutive days, Monday to Friday.
•Patient is willing and able to provide informed consent to participate in the study.

Exclusion Criteria

•Patient is pregnant or has plans for pregnancy during the period of treatment.
•Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response").

Locations (1)

Princess Margaret Cancer Centre (University Health Network)

Toronto, Ontario, Canada

Key Dates

Start Date

October 17, 2024

Primary Completion Date

October 1, 2025

Completion Date

December 1, 2025

Last Updated

December 3, 2024

Enrollment

ESTIMATED participants

Conditions

Head and Neck CancerThoracic CancerAbdominal CancerPelvic Cancer

Interventions

HyperSight Imaging

DEVICE

Contacts

Sean Davidson

CONTACT

437-991-8294 sean.davidson@varian.com

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Advanced Solid TumorAdvanced Malignant Neoplasm+28 more

View study

RECRUITINGPHASE2

A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer

NCT07457346

Head and Neck Cancer Squamous Cell Carcinoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of On-Couch CBCT Image Quality

Inclusion Criteria

Exclusion Criteria

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer

An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial